Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Medicine
- Publicado em
- 1 fev 2020
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis
Zheng Zheng, Ying Guo, Chang-Peng Zou
Descritores MeSH
- Esophageal Neoplasms
- Esophagogastric Junction
- Stomach Neoplasms
- Antibodies, Monoclonal, Humanized
- Survival Analysis
- Randomized Controlled Trials as Topic
- Treatment Outcome
- B7-H1 Antigen
- Humans
- Programmed Cell Death 1 Receptor
Veja também
Estudos relacionados
- The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy
- Eficácia e segurança dos regimes sistêmicos para o adenocarcinoma da junção gástrica e gastroesofágica ressecáveis: uma meta-análise em rede de ensaios controlados randomizados
- Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma
- Comparative efficacy and safety of distinct PD-1 antibodies in unresectable advanced or recurrent gastric and gastroesophageal junction cancer: a network meta-analysis of randomized controlled trials